Article    Table of Contents                    Full Text of this article Free    Figures/Tables List  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Wanner, C.    Wieland, H.    Related Articles in PubMed    PubMed Citation    PubMed

ARTICLE

Elevated Plasma Lipoprotein(a) in Patients with the Nephrotic Syndrome

Christoph Wanner; Daniel Rader; Werner Bartens; Jochen Kramer; H. Bryan Brewer; Peter Schollmeyer; and Heinrich Wieland

15 August 1993 | Volume 119 Issue 4 | Pages 263-269

Objective: To examine the influence of the nephrotic syndrome on lipoprotein(a) (Lp[a]), a plasma lipoprotein associated with atherosclerotic cardiovascular disease independently of low-density lipoproteins. Factors that modulate plasma Lp(a) concentrations are poorly understood.

Patients: A total of 62 patients: 47 with primary kidney disease and 15 with diabetic nephropathy.

Measurements: Lipoprotein(a) levels were determined by enzyme-linked immunosorbent assay. Because apo(a) phenotype has a significant effect on Lp(a) levels, apo(a) isoforms were determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, Western blotting, and immunoblotting; the data were compared with a healthy control group.

Results: Nephrotic patients had significantly higher Lp(a) levels (mean, ± SE, 69 ± 10 mg/dL; median, 46 mg/dL, <0.01) compared with 91 healthy controls (mean, 18 ± 2 mg/dL; median 9 mg/dL). Sixty percent of the patients and 18% of the controls had values greater than 30 mg/dL. Lipoprotein(a) levels correlated significantly with apolipoprotein B, serum cholesterol, and low-density lipoprotein cholesterol but showed no correlation with creatinine, albumin, or proteinuria. Within all apo(a) isoform classes, higher concentrations of Lp(a) were seen in the nephrotic patients compared with controls (P < 0.05). Finally, in nine patients with primary kidney disease and elevated Lp(a) levels, remission of the nephrotic syndrome was induced using immunosuppressive drugs and Lp(a) values decreased dramatically (pretreatment mean, 90 ± 15 mg/dL versus remission mean, 31 ± 8 mg/dL). A decrease in Lp(a) levels was also observed when patients with diabetic nephropathy progressed to end-stage renal disease (nephropathy mean, 56 ± 11 mg/dL versus dialysis mean, 34 ± 10 mg/dL; n = 7).

Conclusions: Most patients with the nephrotic syndrome have Lp(a) concentrations that are substantially elevated compared with controls of the same apo(a) isoform. Because Lp(a) concentrations are substantially reduced when remission of the nephrotic syndrome is induced, it is likely that the nephrotic syndrome results directly in elevation of Lp(a) by an as yet unknown mechanism. The high levels of Lp(a) in the nephrotic syndrome could cause glomerular injury as well as increase the risk for atherosclerosis and thrombotic events associated with this disorder.

Author and Article Information

From the University Hospital of Freiburg, Freiburg, Germany; the National Heart, Lung, and Blood Institute, Bethesda, Maryland.
Requests for Reprints: Christoph Wanner, MD, Department of Medicine, Division of Nephrology, Hugstetterstr. 55 7800 Freiburg, Germany.
Acknowledgments: The authors thank Glenda Talley, Marie Kindt, Barbara Winterrowd, Isolde Friedrich, and Petra Daemisch for their technical assistance. They also thank Gabriele Schulgen for statistical help.
Grant Support: By a grant from the Deutsche Forschungsgemeinschaft Wa 836/1-1.

This article has been cited by other articles:

				B. C.H. Kwan, F. Kronenberg, S. Beddhu, and A. K. Cheung Lipoprotein Metabolism and Lipid Management in Chronic Kidney Disease J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1246 - 1261. [Full Text] [PDF]

				W. A Prescott Jr, D.-a. D Streetman, and D. S Streetman The Potential Role of HMG-CoA Reductase Inhibitors in Pediatric Nephrotic Syndrome Ann. Pharmacother., December 1, 2004; 38(12): 2105 - 2114. [Abstract] [Full Text] [PDF]

				G. A. Kaysen and J. P. Eiserich The Role of Oxidative Stress-Altered Lipoprotein Structure and Function and Microinflammation on Cardiovascular Risk in Patients with Minor Renal Dysfunction J. Am. Soc. Nephrol., March 1, 2004; 15(3): 538 - 548. [Abstract] [Full Text] [PDF]

				L. Vogt, G. D. Laverman, R. P. F. Dullaart, and G. Navis Lipid management in the proteinuric patient: do not overlook the importance of proteinuria reduction Nephrol. Dial. Transplant., January 1, 2004; 19(1): 5 - 8. [Full Text] [PDF]

				D. S. Parsons, D. A. Reaveley, D. V. Pavitt, M. Misra, and E. A. Brown Lipoprotein (a) levels in those with high molecular weight apo (a) isoforms may remain low in a significant proportion of patients with end-stage renal disease Nephrol. Dial. Transplant., September 1, 2003; 18(9): 1848 - 1853. [Abstract] [Full Text] [PDF]

				N. D. Vaziri, K. Liang, and J. S. Parks Acquired lecithin-cholesterol acyltransferase deficiency in nephrotic syndrome Am J Physiol Renal Physiol, May 1, 2001; 280(5): F823 - F828. [Abstract] [Full Text] [PDF]

				C. DOUCET, V. MOOSER, S. GONBERT, F. RAYMOND, J. CHAPMAN, C. JACOBS, and J. THILLET Lipoprotein(a) in the Nephrotic Syndrome: Molecular Analysis ofLipoprotein(a) and Apolipoprotein(a) Fragments in Plasma and Urine J. Am. Soc. Nephrol., March 1, 2000; 11(3): 507 - 513. [Abstract] [Full Text] [PDF]

				T. Soulat, S. Loyau, V. Baudouin, L. Maisonneuve, M.-F. Hurtaud-Roux, N. Schlegel, C. Loirat, and E. Angles-Cano Effect of Individual Plasma Lipoprotein(a) Variations In Vivo on Its Competition With Plasminogen for Fibrin and Cell Binding : An In Vitro Study Using Plasma From Children With Idiopathic Nephrotic Syndrome Arterioscler. Thromb. Vasc. Biol., February 1, 2000; 20(2): 575 - 584. [Abstract] [Full Text] [PDF]

				F. KRONENBERG, E. KUEN, E. RITZ, R. JUNKER, P. KÖNIG, G. KRAATZ, K. LHOTTA, J. F. E. MANN, G. A. MÜLLER, U. NEYER, et al. Lipoprotein(a) Serum Concentrations and Apolipoprotein(a) Phenotypes in Mild and Moderate Renal Failure J. Am. Soc. Nephrol., January 1, 2000; 11(1): 105 - 115. [Abstract] [Full Text]

				S. R. Orth and E. Ritz The Nephrotic Syndrome N. Engl. J. Med., April 23, 1998; 338(17): 1202 - 1211. [Full Text] [PDF]

				J. Galle, J. Bengen, P. Schollmeyer, and C. Wanner Impairment of Endothelium-Dependent Dilation in Rabbit Renal Arteries by Oxidized Lipoprotein(a) : Role of Oxygen-Derived Radicals Circulation, September 15, 1995; 92(6): 1582 - 1589. [Abstract] [Full Text]